1 April 2020 - The following is a statement from Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA) and Biosimilars Canada on COVID-19:

“The Canadian Generic Pharmaceutical Association (CGPA) and Biosimilars Canada continue to work closely with Health Canada, member companies and key stakeholders in the pharmaceutical supply chain to help ensure that Canadian patients continue to have access to high-quality generic and biosimilar medicines.

There have been some reports of demand-related shortages for specific medicines in some Canadian pharmacies due to the pandemic. CGPA and Biosimilars Canada are supportive of actions taken by provincial governments in Canada to limit pharmacy dispensing frequency to help address this issue. Health Canada also advised Canadians on March 30, 2020 that buying more medicine than usual can lead to local drug shortages."

Read Canada Generic Pharmaceutical Association press release